EMNPD

NPs Basic Information
NPs Species Source
NPs Content
NPs Biological Activity
NPs Physi-Chem Properties
NPs ADMET Properties
Similar NPs and Drugs

NPs Basic Information

Download MOL File	Name	Physostigmine
	Molecular Formula	C15H21N3O2
	IUPAC Name*	[(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-methylcarbamate
	SMILES	C[C@@]12CCN([C@@H]1N(C3=C2C=C(C=C3)OC(=O)NC)C)C
	InChI	InChI=1S/C15H21N3O2/c1-15-7-8-17(3)13(15)18(4)12-6-5-10(9-11(12)15)20-14(19)16-2/h5-6,9,13H,7-8H2,1-4H3,(H,16,19)/t13-,15+/m1/s1
	InChIKey	PIJVFDBKTWXHHD-HIFRSBDPSA-N
	Synonyms	physostigmine; Eserine; 57-47-6; Antilirium; Physostol; Esromiotin; (-)-physostigmine; Ezerin; Calabarine; Erserine; Fysostigmin; cogmine; (3aS,8aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl methylcarbamate; eserin; Eserinum; Eserolein, methylcarbamate (ester); Eserine sulfate; CHEMBL94; NSC-30782; 9U1VM840SP; CHEBI:27953; MCV-4484; NSC30782; NCGC00093889-03; DSSTox_CID_3471; [(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-methylcarbamate; DSSTox_RID_77040; DSSTox_GSID_23471; Pyrrolo(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS-cis); Fysostigmin [Czech]; CHEMBL537674; Pyrrolo(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS-cis)-; (3aS,8aR)-1,3a,8-trimethyl-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b]indol-5-yl N-methylcarbamate; CAS-57-47-6; CCRIS 3422; HSDB 3161; MCV 4484; EINECS 200-332-8; Eserolein, methylcarbamate; NIH 10421; NSC 30782; Physostigmine [USP:BAN]; RCRA waste no. P204; physostigmin; UNII-9U1VM840SP; CS 58525; Methyl-carbamic acid, ester with eseroline; Carbamic acid, methyl-, ester with eseroline; (-) physostigmine; Eserine (TN); Physostigmine (USP); Spectrum_000916; Spectrum_001789; ESERINUM [HPUS]; SpecPlus_000381; Prestwick0_000566; Prestwick1_000566; Prestwick2_000566; Prestwick3_000566; Spectrum2_000330; Spectrum2_000757; Spectrum2_001283; Spectrum3_000545; Spectrum3_000901; Spectrum4_000997; Spectrum4_001631; Spectrum4_001913; Spectrum5_000441; Spectrum5_000626; Spectrum5_001672; PHYSOSTIGMINE [MI]; physostigmine.salicylic acid; 1,2,3,3abeta,8abeta-Hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)-indol-5-yl methylcarbamate; PHYSOSTIGMINE [HSDB]; Lopac0_000483; SCHEMBL24044; BSPBio_000352; BSPBio_002189; KBioGR_001433; KBioGR_002061; KBioGR_002533; KBioSS_001396; KBioSS_002279; PHYSOSTIGMINE [VANDF]; (3aS-cis)-1,2,3,3a,8,8a-Hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-ol methylcarbamate (ester); MLS001304022; DivK1c_006477; PHYSOSTIGMINE [MART.]; SPECTRUM1500753; SPBio_000339; SPBio_000774; SPBio_001285; SPBio_002571; PHYSOSTIGMINE [WHO-DD]; BPBio1_000388; cid_657348; GTPL6598; MEGxp0_001872; DTXSID3023471; ACon1_000097; BDBM11023; KBio1_001421; KBio2_001396; KBio2_002278; KBio2_003964; KBio2_004846; KBio2_006532; KBio2_007414; KBio3_001689; KBio3_001842; Eserine, >=98.0% (N); HMS1921G06; HMS2089M11; HMS2236L08; HMS3261B07; BCP19735; Carbamic acid, ester with eseroline; HY-N6608; PHYSOSTIGMINE [USP IMPURITY]; Tox21_111228; Tox21_301591; Tox21_500483; BDBM50004000; BDBM50222010; CCG-38605; MFCD00151090; ZINC91689892; AKOS016843649; Tox21_111228_1; DB00981; LP00483; SDCCGMLS-0066585.P001; SDCCGSBI-0050467.P005; NCGC00093889-01; NCGC00093889-02; NCGC00093889-04; NCGC00093889-05; NCGC00093889-06; NCGC00093889-07; NCGC00093889-08; NCGC00093889-09; NCGC00093889-10; NCGC00093889-12; NCGC00093889-13; NCGC00093889-20; NCGC00255345-01; NCGC00261168-01; AC-15983; Pyrrolo(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS,8aR)-; SMR000718753; SBI-0050467.P004; CS-0034353; EU-0100483; P0406; Physostigmine 100 microg/mL in Acetonitrile; C06535; D00196; E 8375; EN300-23839407; Q410595; Eserine; Antilirium; Physostol; Esromiotin; Ezerin; SR-01000075341-1; WLN: T B556 EN GNTT&J B1 E1 G1 KOVM1; BRD-K25650355-001-02-5; BRD-K25650355-059-02-3; BRD-K25650355-059-12-2; (3aS,8aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl methylcarbamate hydrochloride; (3aS,8aR)-1,3a,8-trimethyl-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b]indol-5-yl N-methylcarbamate; 2-hydroxybenzoic acid; 1,2,3,3A.BETA.,8A.BETA.-HEXAHYDRO-1,3A,8-TRIMETHYLPYRROLO(2,3-B)-INDOL-5-YL METHYLCARBAMATE; Pyrrolo(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, 5-(N-methylcarbamate), (3aS,8aR)-; Pyrrolo[2, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS-cis)-
	CAS	57-47-6
	PubChem CID	5983
	ChEMBL ID	CHEMBL94

*Note: the IUPAC Name was collected from PubChem.

Chemical Classification:	Kingdom: Organic compounds Superclass: Organoheterocyclic compou Class: Indoles and derivatives Subclass: Pyrroloindoles Direct Parent: Pyrroloindoles	ClassyFire Version 1.0 PMID:27867422

NPs Species Source

	Endophyte ID	Endophyte Name	Family	Genus	Taxonomy ID	GenBank ID	Closest GenBank ID	Reference
	Endophyte ID	Endophyte Name	Family	Genus	Taxonomy ID	GenBank ID	Closest GenBank ID	Reference

NPs Content

*Note: The vaules in Content Percentage are calculated by dividing the content value by the maximum content value in NP Content.

**Note: The units with different NP content, due to their incomparable values, are separated into different tables.

NPs Biological Activity

	Bioactivity Name	Target ID	Target Name	Target Type	Target Organism	Target Organism ID	Potency of Bioactivity	Activity Type	Value	Unit	Endophyte ID	Endophyte Name
	Bioactivity Name	Target ID	Target Name	Target Type	Target Organism	Target Organism ID	Potency of Bioactivity	Activity Type	Value	Unit	Endophyte ID	Endophyte Name

NPs Physi-Chem Properties

Molecular Weight:	275.35	ALogp:	0.7
HBD:	1	HBA:	4
Rotatable Bonds:	2	Lipinski's rule of five:	Accepted
Polar Surface Area:	44.8	Aromatic Rings:	3
Heavy Atoms:	20	QED Weighted:	0.854

NPs ADMET Properties*

ADMET: Absorption

Caco-2 Permeability:	-4.884	MDCK Permeability:	0.00002150
Pgp-inhibitor:	0.054	Pgp-substrate:	0.824
Human Intestinal Absorption (HIA):	0.981	20% Bioavailability (F20%):	0.996
30% Bioavailability (F30%):	0.998

ADMET: Distribution

Blood-Brain-Barrier Penetration (BBB):	0.993	Plasma Protein Binding (PPB):	37.48%
Volume Distribution (VD):	1.456	Fu:	78.58%

ADMET: Metabolism

CYP1A2-inhibitor:	0.155	CYP1A2-substrate:	0.316
CYP2C19-inhibitor:	0.082	CYP2C19-substrate:	0.936
CYP2C9-inhibitor:	0.02	CYP2C9-substrate:	0.247
CYP2D6-inhibitor:	0.535	CYP2D6-substrate:	0.881
CYP3A4-inhibitor:	0.029	CYP3A4-substrate:	0.224

ADMET: Excretion

Clearance (CL):

7.772

Half-life (T1/2):

0.607

ADMET: Toxicity

hERG Blockers:	0.143	Human Hepatotoxicity (H-HT):	0.031
Drug-inuced Liver Injury (DILI):	0.051	AMES Toxicity:	0.353
Rat Oral Acute Toxicity:	0.989	Maximum Recommended Daily Dose:	0.902
Skin Sensitization:	0.38	Carcinogencity:	0.876
Eye Corrosion:	0.003	Eye Irritation:	0.013
Respiratory Toxicity:	0.906

*Note: the ADMET properties was calculated by ADMETlab 2.0. Reference: PMID: 33893803.

Similar Compounds*

Compounds similar to EMNPD with top10 similarity:

Similar NPs					Similar Drugs
NPs ID	NPs 2D Structure	Similarity Score			TTD ID	Drug 2D Structure	Similarity Score
ENC000081		0.338			D09OBB		0.299
ENC004190		0.262			D0W6DG		0.284
ENC004191		0.262			D0WO8W		0.265
ENC002065		0.256			D0T7ZQ		0.263
ENC003790		0.256			D03XES		0.253
ENC002280		0.247			D0T6WT		0.248
ENC002187		0.247			D08USJ		0.244
ENC004193		0.244			D02IOH		0.241
ENC004192		0.244			D0T3HY		0.236
ENC004993		0.244			D02DPU		0.235

*Note: the compound similarity was calculated by RDKIT.